Skip to content
DraconiticResearch
Search Sources API
220,595 studies31 sourcesUpdated 45 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

KDM1A-associated tumor–myeloid communication and extracellular vesicle-mediated microglia-like responses in lung cancer brain metastasis

Abstract

IntroductionLung cancer brain metastasis is shaped by reciprocal interactions between tumor cells and the brain microenvironment, yet whether KDM1A/LSD1 influences this communication through tumor-derived extracellular vesicles (EVs) remains unclear.MethodsHere, we combined within-patient single-cell transcriptomic analysis with genetic and pharmacological LSD1 perturbation, EV-based functional assays, and an intracranial xenograft model to define an LSD1-associated tumor-myeloid communication phenotype.ResultsSingle-cell analysis identified a reproducible KDM1A co-expression-associated tumor-cell state characterized by coordinated communication- and microenvironment-remodeling programs and recurrent APP-CD74- and MDK-related signaling patterns. Among the prioritized candidates, MDK showed the most consistent experimental response to LSD1 knockout, with concordant reductions in donor-cell mRNA, cellular protein and EV-associated protein. Functionally, EVs derived from LSD1-deficient tumor cells shifted HMC3 microglia-like cells toward a mixed inflammatory and immunoregulatory state and altered their secretory output. Conditioned medium from these EV-exposed HMC3 cells subsequently suppressed H1299 proliferation and enhanced apoptosis, indicating a secondary tumor-myeloid-tumor paracrine effect. Pharmacological LSD1 inhibition produced a partially overlapping functional phenotype. In mice with established intracranial tumors, LSD1-KO-EV treatment was associated with lower endpoint ex vivo brain bioluminescence, with representative H&E sections showing a qualitatively concordant pattern.DiscussionThese findings support EV-mediated tumor-myeloid communication as one consequence of LSD1 perturbation and nominate MDK-associated EV remodeling for direct mechanistic testing.

Related

  1. Hypoxic microglia induce oligodendrocyte injury through lactate associated extracellular vesicles and toll like receptor four signaling
    Yan Wen, Dongdong Li, Jiajia Lin +2
    3 BiotechPeer-reviewedLicence not statedFull textNeurologyPMC
  2. Microglia and border-associated macrophages play opposite roles in cerebrovascular and leukocyte responses under systemic inflammation in male mice.
    Ana Rita Brás, Nikolett Lénárt, Damien Levard +12
    Nature communicationsPeer-reviewedCC BY-NC-NDFull textNeurologyEurope PMC
  3. Analysis of prognostic features associated with extracellular matrix and lymph node metastasis in colorectal cancer.
    Xuefang Chen, Feng Qiu, Rujie Peng +4
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  4. Microglia-derived Small Extracellular Vesicles Promote Bone Marrow Monocyte Expansion and Recruitment in Glioblastoma.
    I. Albuja, M. Quiralte, N. Panda +6
    bioRxivPreprintAll rights reservedFull textOncologybioRxivPMC
  5. The mitochondrial unfolded protein response in human microglia disrupts neuronal–glial communication and promotes senescence
    Maria Jose Perez J., Alicia Lam, Christin Weissleder +11
    Nature NeurosciencePeer-reviewedCC BYFull text15 citedNeurologyOpenAlex
BibTeX
@article{li2026kdm1aassociated,
  title = {{KDM1A-associated tumor–myeloid communication and extracellular vesicle-mediated microglia-like responses in lung cancer brain metastasis}},
  author = {Zi-Hao Li and Juan-Juan Peng and Bao-Xin-Zi Liu and Qing-Feng Li and Mian-Hua Wu and Lei Wang and Zhong-Rui Li},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = nov,
  doi = {10.3389/fphar.2026.1912724},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1912724},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - KDM1A-associated tumor–myeloid communication and extracellular vesicle-mediated microglia-like responses in lung cancer brain metastasis
AU  - Zi-Hao Li
AU  - Juan-Juan Peng
AU  - Bao-Xin-Zi Liu
AU  - Qing-Feng Li
AU  - Mian-Hua Wu
AU  - Lei Wang
AU  - Zhong-Rui Li
PY  - 2026
DA  - 2026/11/13
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1912724
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1912724
AB  - IntroductionLung cancer brain metastasis is shaped by reciprocal interactions between tumor cells and the brain microenvironment, yet whether KDM1A/LSD1 influences this communication through tumor-derived extracellular vesicles (EVs) remains unclear.MethodsHere, we combined within-patient single-cell transcriptomic analysis with genetic and pharmacological LSD1 perturbation, EV-based functional assays, and an intracranial xenograft model to define an LSD1-associated tumor-myeloid communication phenotype.ResultsSingle-cell analysis identified a reproducible KDM1A co-expression-associated tumor-cell state characterized by coordinated communication- and microenvironment-remodeling programs and recurrent APP-CD74- and MDK-related signaling patterns. Among the prioritized candidates, MDK showed the most consistent experimental response to LSD1 knockout, with concordant reductions in donor-cell mRNA, cellular protein and EV-associated protein. Functionally, EVs derived from LSD1-deficient tumor cells shifted HMC3 microglia-like cells toward a mixed inflammatory and immunoregulatory state and altered their secretory output. Conditioned medium from these EV-exposed HMC3 cells subsequently suppressed H1299 proliferation and enhanced apoptosis, indicating a secondary tumor-myeloid-tumor paracrine effect. Pharmacological LSD1 inhibition produced a partially overlapping functional phenotype. In mice with established intracranial tumors, LSD1-KO-EV treatment was associated with lower endpoint ex vivo brain bioluminescence, with representative H&E sections showing a qualitatively concordant pattern.DiscussionThese findings support EV-mediated tumor-myeloid communication as one consequence of LSD1 perturbation and nominate MDK-associated EV remodeling for direct mechanistic testing.
SN  - 1663-9812
ER  -